DESTINY PWS Study (C601, Phase III)
The DESTINY PWS is a 15-week, double-blind, placebo-controlled Phase III study in patients with genetically-confirmed PWS who are ages 4 years and older.
Further information about the study can be found at: https://www.clinicaltrials.gov/ct2/show/NCT03440814
Further information about the study can also be obtained from a Webinar presented by the Foundation for Prader-Willi Research which is accessible at https://www.fpwr.org/clinical-trials/dccr
DESTINY PWS Open-Label Extension Study (C602, Phase III)
C602 is a 52-week, open-label Phase III study that is open to individuals who have completed DESTINY PWS and meet certain other criteria.After completion of 1 year in this study, subjects will have the option to continue treatment for up to 2 additional years.
Further information about the study can be found at: https://www.clinicaltrials.gov/ct2/show/NCT03714373